Reproductive and hormonal risk factors for sarcoidosis: a nested case–control study

[1] Arkema EV(1999)Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999 Am J Respir Crit Care Med 160 736-755

[2] Grunewald J(2016)Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden Eur Respir J 48 1690-1699

[3] Kullberg S(2004)Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production Curr Drug Targets Inflamm Allergy 3 97-104

[4] Eklund A(1990)Sarcoidosis and pregnancy: a review with results of a retrospective survey J Intern Med 227 221-224

[5] Askling J(2020)Maternal and infant outcomes in sarcoidosis pregnancy: a Swedish population-based cohort study of first births Respir Res 21 225-641

[6] Salem ML(2012)Reproductive and hormonal factors in relation to incidence of sarcoidosis in US Black women: the Black Women's Health Study Am J Epidemiol 176 635-466

[7] Selroos O(2011)Reproductive hormones and the menopause transition Obstet Gynecol Clin N Am 38 455-24

[8] Köcher L(2003)Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort—evaluation of risk factors and their interactions Scand J Public Health Suppl 61 18-447

[9] Rossides M(2021)Positive predictive value of sarcoidosis identified in an administrative healthcare registry: a validation study Epidemiology 32 444-1399

[10] Remaeus K(2016)Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases Br J Cancer 115 1391-635

[1] Arkema EV(1999)Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999 Am J Respir Crit Care Med 160 736-755

[2] Grunewald J(2016)Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden Eur Respir J 48 1690-1699

[3] Kullberg S(2004)Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production Curr Drug Targets Inflamm Allergy 3 97-104

[4] Eklund A(1990)Sarcoidosis and pregnancy: a review with results of a retrospective survey J Intern Med 227 221-224

[5] Askling J(2020)Maternal and infant outcomes in sarcoidosis pregnancy: a Swedish population-based cohort study of first births Respir Res 21 225-641

[6] Salem ML(2012)Reproductive and hormonal factors in relation to incidence of sarcoidosis in US Black women: the Black Women's Health Study Am J Epidemiol 176 635-466

[7] Selroos O(2011)Reproductive hormones and the menopause transition Obstet Gynecol Clin N Am 38 455-24

[8] Köcher L(2003)Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort—evaluation of risk factors and their interactions Scand J Public Health Suppl 61 18-447

[9] Rossides M(2021)Positive predictive value of sarcoidosis identified in an administrative healthcare registry: a validation study Epidemiology 32 444-1399

[10] Remaeus K(2016)Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases Br J Cancer 115 1391-635